Q-omics provides the consensus-scored PIH1D2 profile across patient tissues and cancer cell-line models. PIH1D2 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PIH1D2 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, PIH1D2 RNA expression shows 19,263 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KICH, and UVM as cancer lineages where PIH1D2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PIH1D2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PIH1D2 survival associations across molecular data types. PIH1D2 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PIH1D2 RNA expression–survival associations across cancer types. High PIH1D2 expression shows unfavorable associations in LGG, KICH and LIHC, but favorable associations in KIRC, KIRP and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PIH1D2 RNA expression.
This table summarizes PIH1D2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PIH1D2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PIH1D2 shows lower tumor expression in KICH, THCA, LUSC and LUAD and higher tumor expression in COAD and LIHC. The KICH box plot shows higher PIH1D2 RNA expression in normal versus tumor tissue (log2 FC = −2.284, t-test p < 0.001).
This table shows molecular features associated with PIH1D2 in patient tissues and cancer cell lines. In patient samples, PIH1D2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PIH1D2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Lymphoma.
